These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32280079)

  • 1. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
    Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation.
    Grisolia P; Tufano R; Iannarone C; De Falco A; Carlino F; Graziano C; Addeo R; Scrima M; Caraglia F; Ceccarelli A; Nuzzo PV; Cossu AM; Forte S; Giuffrida R; Orditura M; Caraglia M; Ceccarelli M
    J Transl Med; 2024 Oct; 22(1):938. PubMed ID: 39407254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
    Widschwendter M; Rosenthal AN; Philpott S; Rizzuto I; Fraser L; Hayward J; Intermaggio MP; Edlund CK; Ramus SJ; Gayther SA; Dubeau L; Fourkala EO; Zaikin A; Menon U; Jacobs IJ
    Lancet Oncol; 2013 Nov; 14(12):1226-32. PubMed ID: 24140203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating tumour pathology information into breast cancer risk prediction algorithms.
    Mavaddat N; Rebbeck TR; Lakhani SR; Easton DF; Antoniou AC
    Breast Cancer Res; 2010; 12(3):R28. PubMed ID: 20482762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
    Levy-Lahad E; Lahad A; Eisenberg S; Dagan E; Paperna T; Kasinetz L; Catane R; Kaufman B; Beller U; Renbaum P; Gershoni-Baruch R
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3232-6. PubMed ID: 11248061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
    Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
    Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
    Johnson L; Sammel MD; Domchek S; Schanne A; Prewitt M; Gracia C
    Fertil Steril; 2017 May; 107(5):1256-1265.e6. PubMed ID: 28476184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
    Metcalfe KA; Lubinski J; Gronwald J; Huzarski T; McCuaig J; Lynch HT; Karlan B; Foulkes WD; Singer CF; Neuhausen SL; Senter L; Eisen A; Sun P; Narod SA;
    Clin Genet; 2018 May; 93(5):1063-1068. PubMed ID: 29206279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM).
    Boulenouar ACS; Coulet F; Bendiab FMT; Boudinar FZ; Senhadji R
    Gulf J Oncolog; 2018 May; 1(27):31-37. PubMed ID: 30145549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.